This month, Hoosier Cancer Research Network (HCRN) features our member Dana-Farber Cancer Institute, and the Institute’s Guru P. Sonpavde, MD, a long-time HCRN investigator.

Research Interests:

Guru P. Sonpavde, MD is the Bladder Cancer Director at the Dana-Farber Cancer Institute, an affiliate of Harvard Medical School. At Dana-Farber, he leads multiple cutting-edge clinical trials studying novel immunotherapy and targeted drugs to cure bladder cancer. He is the also the national or international principal investigator of multiple clinical trials for bladder cancer patients. Additionally, he is on the steering committees of several major clinical trials attempting to improve outcomes and change the standard of care for bladder cancer patients. He has also led translational projects and developed prognostic classifications and clinical endpoints focused on bladder cancer. He is a member of Southwest Oncology Group (SWOG) and Bladder Cancer Task Force of the U.S. NCI GU Steering Committee.

Educational background:

• Medical School: Christian Medical College, Vellore, India
• Internal Medicine Residency: Nassau University Medical Center, East Meadow, N.Y.
• Hematology-Oncology Fellowship: Indiana University Medical Center, Indianapolis, Ind.

Dr. Sonpavde enjoys:

• Tennis, hiking, and running.
• History/Politics/Economics.
• Electronic dance music.

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 210 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 8,500 subjects have participated in Hoosier Cancer Research Network clinical trials.